Inspire therapy is a clinically proven sleep apnea treatment option.
The STAR clinical trial, involving 126 Obstructive Sleep Apnea (OSA) patients across the United States and Europe, began in 2010 to evaluate the safety and efficacy of Inspire therapy. One-year STAR Trial results were published in the New England Journal of Medicine1, in January 2014, and Inspire therapy received approval by the United States Food and Drug Administration (FDA) in April of that year.
Long-term STAR Trial outcomes show that sleep apnea patients receiving Inspire therapy experienced significant and sustained reductions in sleep apnea events and significant improvements in both quality of life and daytime functioning*, as measured by various questionnaires.
Some notable outcomes include:
The STAR Clinical Trial
Learn about the results from the STAR clinical trial.
*As measured by the Epworth Sleepiness Scale and Functional Outcomes of Sleep Questionnaire.
References: 1. Stollo et al., NEJM 2014. 2. Woodson et al., OTO-HNS 2015